Sensitivity of the Elecsys Nucleocapsid Assay for the Detection of Preceding SARS-CoV-2 Infections.

Brian E GrunauJanessa TomMichael Asamoah-BoahengSheila F O'BrienSteven J DrewsSadaf SediqiPascal M LavoieVilte BarakauskasDavid M Goldfarb

Published in: Open forum infectious diseases (2022)

Nucleocapsid serological assay sensitivity to identify severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections among vaccinees and for Omicron cases is unclear. In this prospective study, the Elecsys nucleocapsid assay was 89% sensitive in identifying SARS-CoV-2 infections 14-607 days pre-blood collection. Sensitivity was similar when comparing by vaccination status, and in Omicron (vs pre-Omicron) cases.

Keyphrases

respiratory syndrome coronavirus
sars cov
high throughput
coronavirus disease
label free
loop mediated isothermal amplification